Categories Health Care

InspireMD, ReWalk Robotics decline on stock offering

Two Israeli firms – InspireMD (NYSE: NSPR) and ReWalk Robotics (NASDAQ: RWLK) – saw their shares fall during the pre-market hours of Thursday on announcements of their respective stock offerings.

Shares of Tel Aviv-based InspireMD plunged 30% during morning trade after the company priced its public offering of 486,957 common stock at $5 apiece. The company, which makes Carotid Embolic Prevention System, expects $2.4 million in net proceeds from the offering, which will close on April 8, 2019.

The company has lost 86% of its value in the trailing 52 weeks. For the year-to-date period, the stock is down 12%.

READ: LYFT AND SIX OTHER COMPANIES WENT PUBLIC IN MARCH. FULL LIST

Meanwhile, ReWalk Robotics stock slipped 3% during the pre-market hours after the prosthetics firm said it would offer about 816,914 ordinary shares at a purchase price of $5.2025 apiece in a registered direct offering.

ReWalk will also issue unregistered warrants to buy about 408,457 ordinary shares, with a term of 5.5 years and exercise price of $5.14 per ordinary share.

The company, which makes wearable robotic exoskeletons for individuals with lower limb disabilities, expects gross proceeds of approximately $4.25 million. The offering is expected to close on April 8.

The stock is down 80% in the trailing 52 weeks. For the year-to-date period, the stock is up 6.2%.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Kroger (KR) looks set to start 2023 with new vigor. Is the stock a buy?

The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new

Dollar General (DG): Five takeaways from the discount store’s Q3 earnings report

Shares of Dollar General Corporation (NYSE: DG) were up over 2% on Friday, a day after the company delivered mixed results for the third quarter of 2022 and lowered its

Salesforce stock hit by weak guidance, co-CEO’s exit. What next?

For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top